Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Around 20% to 30% of meningiomas are aggressive and potentially deadly.
Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.
Allergy meds were linked to longer survival among cancer patients treated with immune checkpoint inhibitors.
Extra vaccine doses, monoclonal antibodies and antivirals can help prevent severe illness.
Discovery in head and neck cancers may open door for targeted immune-boosting drugs
“While this approach is not restricted to analyzing tumor tissues, there are obvious applications for better understanding cancer."
Researchers hope to easily identify which colon cancer patients are unlikely to benefit from immune checkpoint inhibitors (ICIs).
New insights into why men fail to mount as powerful an immune response to many cancers as women do.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
Removing naive T cells before a stem cell transplant in certain cancer patients may prevent chronic graft-versus-host disease.
Immunotherapy response tends to follow a pattern, while resistance looks different from patient to patient.
Medications that block the PSGL-1 protein promote an anti-tumor immune response in people with melanoma.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
Some types of lymphoma are considered AIDS-defining illnesses, but that doesn’t mean they’re caused by HIV itself.
People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.